University of California, San Diego

Evidence for different accretion regimes in GRO J1008-57 (2017) Kühnel M, Furst F, Pottschmidt K, Kreykenbohm I, Ballhausen R, Falkner S, Rothschild RE, et al. Journal article Inversion of the decay of the cyclotron line energy in Hercules X-1 (2017) Staubert R, Klochkov D, Fuerst F, Wilms J, Rothschild RE, Harrison F Journal article A precessing Be disc as a possible model for occultation events in GX 304-1 (2017) Kühnel M, Rothschild RE, Okazaki AT, Müller S, Pottschmidt K, Ballhausen R, Choi J, et al. Journal article A Suzaku, NuSTAR, and XMM-Newton view on variable absorption and relativistic reflection in NGC 4151 (2017) Beuchert T, Markowitz AG, Dauser T, Garcia J, Keck ML, Wilms J, Kadler M, et al. Journal article Electronic structure and ultrafast dynamics of FeAs-based superconductors by angle- and time-resolved photoemission spectroscopy (2017) Avigo I, Thirupathaiah S, Rienks EDL, Rettig L, Charnukha A, Ligges M, Cortes R, et al. Journal article Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies (2017) Kohl Z, Schlachetzki J, Feldewerth J, Hornauer P, Muench M, Adame A, Riemenschneider MJ, et al. Journal article SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution